Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Issued
Ratios

Neurocrine Biosciences (NBIX) Leases (2019 - 2025)

Neurocrine Biosciences' Leases history spans 7 years, with the latest figure at $455.4 million for Q4 2025.

  • For Q4 2025, Leases fell 10.6% year-over-year to $455.4 million; the TTM value through Dec 2025 reached $455.4 million, down 10.6%, while the annual FY2025 figure was $455.4 million, 10.6% down from the prior year.
  • Leases reached $455.4 million in Q4 2025 per NBIX's latest filing, down from $468.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $509.4 million in Q4 2024 to a low of $80.8 million in Q3 2023.
  • Average Leases over 5 years is $221.1 million, with a median of $99.1 million recorded in 2021.
  • Peak YoY movement for Leases: fell 10.88% in 2023, then soared 220.85% in 2024.
  • A 5-year view of Leases shows it stood at $97.2 million in 2021, then fell by 10.49% to $87.0 million in 2022, then surged by 128.74% to $199.0 million in 2023, then soared by 155.98% to $509.4 million in 2024, then dropped by 10.6% to $455.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Leases are $455.4 million (Q4 2025), $468.9 million (Q3 2025), and $492.3 million (Q2 2025).